Eli Lilly’s October 2024 material transfer agreement granted only non-exclusive research rights to evaluate Peptron’s SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained one- to six-month peptide release, without commercial manufacturing or licensing provisions. Nearly two years later, no binding technology-transfer or commercial deal has been disclosed, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal long-acting incretin technology. July 2026 statements further clarified that key candidates like tirzepatide fall outside the collaboration, prompting sharp share-price drops and underscoring limited near-term prospects. With roughly seven weeks remaining until the October 7 resolution date, the 87.5% market-implied probability for No reflects the absence of any announced commercial milestone and the short timeline for a surprise licensing announcement.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado13% probabilidad
$11,264 Vol.
$11,264 Vol.
7 oct 2026
13% probabilidad
$11,264 Vol.
$11,264 Vol.
7 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 material transfer agreement granted only non-exclusive research rights to evaluate Peptron’s SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained one- to six-month peptide release, without commercial manufacturing or licensing provisions. Nearly two years later, no binding technology-transfer or commercial deal has been disclosed, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal long-acting incretin technology. July 2026 statements further clarified that key candidates like tirzepatide fall outside the collaboration, prompting sharp share-price drops and underscoring limited near-term prospects. With roughly seven weeks remaining until the October 7 resolution date, the 87.5% market-implied probability for No reflects the absence of any announced commercial milestone and the short timeline for a surprise licensing announcement.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$11,264Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 material transfer agreement granted only non-exclusive research rights to evaluate Peptron’s SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained one- to six-month peptide release, without commercial manufacturing or licensing provisions. Nearly two years later, no binding technology-transfer or commercial deal has been disclosed, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal long-acting incretin technology. July 2026 statements further clarified that key candidates like tirzepatide fall outside the collaboration, prompting sharp share-price drops and underscoring limited near-term prospects. With roughly seven weeks remaining until the October 7 resolution date, the 87.5% market-implied probability for No reflects the absence of any announced commercial milestone and the short timeline for a surprise licensing announcement.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$11,264Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 material transfer agreement granted only non-exclusive research rights to evaluate Peptron’s SmartDepot ultrasonic spray-dried PLGA microsphere platform for sustained one- to six-month peptide release, without commercial manufacturing or licensing provisions. Nearly two years later, no binding technology-transfer or commercial deal has been disclosed, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal long-acting incretin technology. July 2026 statements further clarified that key candidates like tirzepatide fall outside the collaboration, prompting sharp share-price drops and underscoring limited near-term prospects. With roughly seven weeks remaining until the October 7 resolution date, the 87.5% market-implied probability for No reflects the absence of any announced commercial milestone and the short timeline for a surprise licensing announcement.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes